Generic Name and Formulations:
Ibuprofen 100mg/mL; for IV infusion after dilution.
Cumberland Pharmaceuticals, Inc.
Indications for CALDOLOR:
Mild-to-moderate pain. Moderate-to-severe pain adjunct to opioids. Fever.
Use lowest effective dose for shortest duration. ≥18yrs: Give by IV infusion over 30 mins. Maintain adequate hydration. Pain: 400mg–800mg every 6 hours as needed. Fever: initially 400mg, followed by 400mg every 4–6 hours or 100–200mg every 4 hours as needed. Max: 3200mg/day.
<6mos: not established. Use lowest effective dose for shortest duration. Give by IV infusion over 10 mins. Maintain adequate hydration. Pain and fever (≥6mos–<12yrs): 10mg/kg up to max single dose of 400mg every 4–6 hours as needed; max: 40mg/kg or 2400mg per day, whichever is less; (12–17yrs): 400mg every 4–6 hours as needed; max: 2400mg/day.
Aspirin allergy. Coronary artery bypass graft surgery.
Increased risk of serious cardiovascular events (including MI, stroke). Avoid in recent MI, severe heart failure; if necessary, monitor. Increased risk of serious GI adverse events (including inflammation, bleeding, ulceration, perforation). History of ulcer disease and/or GI bleeding. Hypertension; monitor BP closely. Hepatic or renal impairment. Discontinue if signs/symptoms of liver or renal disease develop, or if abnormal LFTs persist or worsen. Dehydration. Hypovolemia. Advanced renal disease: not recommended. Hyperkalemia. Coagulation disorders. Monitor CBCs, blood chemistry, hepatic, renal, and ocular function in long-term therapy. Pre-existing asthma. May mask signs of infection or fever. Discontinue at 1st sign of rash or any other hypersensitivity. Elderly. Debilitated. Labor & delivery. Pregnancy (3rd trimester; avoid). Nursing mothers.
Avoid concomitant aspirin, salicylates (eg, diflunisal, salsalate) or other NSAIDs. Increased risk of GI bleed with anticoagulants, antiplatelets, oral corticosteroids, SSRIs, SNRIs, smoking, alcohol, or prolonged NSAID therapy; monitor. May antagonize, or increase risk of renal failure with diuretics (eg, loop or thiazides), ACE inhibitors (eg, captopril), ARBs (eg, losartan), or β-blockers; monitor closely. Potentiates digoxin; monitor levels. May potentiate lithium, methotrexate, cyclosporine; monitor for toxicity. Concomitant with pemetrexed may increase risk of pemetrexed-associated myelosuppression, renal, and GI toxicity.
NSAID (propionic acid deriv.).
Nausea, flatulence, vomiting, headache, hemorrhage, dizziness; cardiovascular thrombotic events, GI ulcer/bleed, hepatotoxicity, renal toxicity, hypersensitivity reactions, peripheral edema, anemia/blood dyscrasias, hypertension.
Single-dose vials (8mL)—25
- Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation
- Navigation Programs Most Effective in Increasing Follow-up Colonoscopy
- New Class of Clinical Trial Enhances Research on Cancer Care Delivery
- Specialized Interventions Reduce Aberrant Opioid Behaviors in Cancer Patients
- Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC
- Anticancer Properties of The Probiotic Kefir: A Review
- Navigating the Transition From Treatment to Breast Cancer Survivor
- Combining Radiation, Immunotherapy: An Emerging Challenge for Oncology Nursing
- Naldemedine Effective for Opioid-Induced Constipation in Cancer Pain
- Disruptions to Circadian Rhythm Linked to Prostate Cancer Surgery Regret
- Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy
- Novel Predictive Model More Effectively Identifies Risk for Lung Cancer
- Long-Term Eltrombopag Increases Platelet Counts, Decreases Bleeding in ITP
- Overall Survival Increase for Melanoma Brain Metastases
- Prophylactic Prochloperazine Ineffective for Opioid-induced Nausea/Vomiting in Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|